Lexaria Bioscience Corp. Announces Milestone of 60 Patents Granted Globally

Kelowna, British Columbia — January 22, 2026 — Leads & Copy — Lexaria Bioscience Corp. (Nasdaq: LEXX) announced it has reached a milestone of 60 valid patents granted worldwide.

The company has been diligently pursuing legal recognition of its innovations. Six new patents have been granted since the previous update on October 9, 2025.

Lexaria has received its first patent in Australia in patent Family #20, Compositions and Methods for Sublingual Delivery of Nicotine, where it has existing granted patents in the US, Canada, and Japan.

The company has received its first European Union patent in patent Family #21, Compositions and Methods for Treating Hypertension, where it already has 3 US granted patents. Europe is considered the 2nd-largest hypertension market in the world.

In patent Family #24, Compositions and Methods for Treating Epilepsy, Lexaria has received 2 new Australian patents and 1 new European Union patent. The company now has a total of 6 US patents; 4 Australian patents; and 1 European Union patent in this family.

Lexaria has received 1 new US patent in patent Family #27, Compositions and Methods for Treating Diabetes, bringing the total to 2 US patents in this family.

Lexaria is reminding shareholders to vote their shares in the upcoming Annual Meeting on January 27, 2026, at 1:00 PM PT. Stockholders holding common stock at the close of business on December 1, 2025, are entitled to vote at the meeting. The company is asking stockholders to follow the Board of Directors’ recommendation to vote FOR all proposals.

The proxy statement and annual report to security holders are available online at: www.colonialstock.com/LEXX2026. Shareholders are encouraged to read the proxy statement and annual report filed in connection with the Meeting in detail and cast their votes prior to the proxy voting deadline (4:00 PM PT on January 26, 2026).

DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 60 patents granted and additional patents pending worldwide.

George Jurcic – Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202

Source: Lexaria Bioscience Corp.